↓ Skip to main content

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Overview of attention for article published in BMC Cancer, December 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
33 Mendeley
Title
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
Published in
BMC Cancer, December 2011
DOI 10.1186/1471-2407-11-515
Pubmed ID
Authors

Sucheta Telang, Mary Ann Rasku, Amy L Clem, Karen Carter, Alden C Klarer, Wesley R Badger, Rebecca A Milam, Shesh N Rai, Jianmin Pan, Hana Gragg, Brian F Clem, Kelly M McMasters, Donald M Miller, Jason Chesney

Abstract

We previously found that administration of an interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted CD4(+)CD25(HI)Foxp3(+) regulatory T cells and expanded melanoma-specific CD8(+) T cells. The goal of this study was to assess the clinical efficacy of DAB/IL2 in an expanded cohort of stage IV melanoma patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 18%
Student > Bachelor 5 15%
Researcher 5 15%
Other 4 12%
Student > Master 3 9%
Other 5 15%
Unknown 5 15%
Readers by discipline Count As %
Medicine and Dentistry 11 33%
Biochemistry, Genetics and Molecular Biology 6 18%
Immunology and Microbiology 6 18%
Agricultural and Biological Sciences 3 9%
Engineering 1 3%
Other 0 0%
Unknown 6 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2012.
All research outputs
#3,455,952
of 12,372,945 outputs
Outputs from BMC Cancer
#908
of 4,558 outputs
Outputs of similar age
#57,608
of 218,604 outputs
Outputs of similar age from BMC Cancer
#55
of 289 outputs
Altmetric has tracked 12,372,945 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 4,558 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 218,604 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 289 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.